Psychedelic and nutraceutical brand Cybin Corp. and drug delivery company IntelGenx have partnered to develop oral dissolving film for psilocybin consumption.
Why Does It Matter?
Cybin Chief Executive Officer Paul Glavine says "orally-dissolving psilocybin film" bypasses the digestive system and provides "faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief."
Chief Medical Officer Jukka Karjalainen noted that orally-dissolving psilocybin expects to produce higher bioavailability levels than pills. The doctor added that the film would have a fraction of the dosage required in a capsule.
"Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner," Karjalainen said.
The agreement marks the latest bit of activity for the psychedelics company.
Last week, the company announced it entered into a reverse takeover agreement with mining issuer Clarmin Explorations Inc. (TSX.V: CX).
Related links:
Cybin Partners With Toronto Centre For Psychedelic Science For Psilocybin Research Project
'Psyched': Military Invests $27M In Psychedelic Research, Atai Launches DTx Platform, Psilocybin Decriminalization Rejected In Iowa
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.